Influence of imprecision on ROC curve analysis for cardiac markers

Peter Kupchak; Alan H.B. Wu; Farooq Ghani; L. Kristen Newby; E. Magnus Ohman; Robert H. Christenson

doi:10.1373/clinchem.2005.064477

Influence of imprecision on ROC curve analysis for cardiac markers

Peter Kupchak, Alan H.B. Wu, Farooq Ghani, L. Kristen Newby, E. Magnus Ohman, Robert H. Christenson

Research output: Contribution to journal › Article › peer-review

26 Citations (Scopus)

Abstract

Background: There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events. Methods: Using existing data from 2 published clinical trials, we used a resampling method to statistically introduce 5%, 10%, and 20% imprecision to results for B-type natriuretic peptide (BNP) and cardiac troponin I (cTni) and examined its impact on ROC curve analysis. Results: Superimposition of artificial imprecision produced no significant difference in the area under the ROC curve observed for BNP for diagnosis of heart failure or for cTnI for 30-day risk stratification of patients with ACS. Conclusion: Assay imprecision does not appear to be a critical determinant in the interpretation of cardiac marker results for patients with heart disease.

Original language	English
Pages (from-to)	752-753
Number of pages	2
Journal	Clinical Chemistry
Volume	52
Issue number	4
DOIs	https://doi.org/10.1373/clinchem.2005.064477
Publication status	Published - Apr 2006
Externally published	Yes

Access to Document

10.1373/clinchem.2005.064477

Cite this

@article{a5d6a14126fa4c7da9db98bfb24e1c94,

title = "Influence of imprecision on ROC curve analysis for cardiac markers",

abstract = "Background: There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events. Methods: Using existing data from 2 published clinical trials, we used a resampling method to statistically introduce 5%, 10%, and 20% imprecision to results for B-type natriuretic peptide (BNP) and cardiac troponin I (cTni) and examined its impact on ROC curve analysis. Results: Superimposition of artificial imprecision produced no significant difference in the area under the ROC curve observed for BNP for diagnosis of heart failure or for cTnI for 30-day risk stratification of patients with ACS. Conclusion: Assay imprecision does not appear to be a critical determinant in the interpretation of cardiac marker results for patients with heart disease.",

author = "Peter Kupchak and Wu, {Alan H.B.} and Farooq Ghani and Newby, {L. Kristen} and Ohman, {E. Magnus} and Christenson, {Robert H.}",

year = "2006",

month = apr,

doi = "10.1373/clinchem.2005.064477",

language = "English",

volume = "52",

pages = "752--753",

journal = "Clinical Chemistry",

issn = "0009-9147",

publisher = "American Association for Clinical Chemistry Inc.",

number = "4",

}

TY - JOUR

T1 - Influence of imprecision on ROC curve analysis for cardiac markers

AU - Kupchak, Peter

AU - Wu, Alan H.B.

AU - Ghani, Farooq

AU - Newby, L. Kristen

AU - Ohman, E. Magnus

AU - Christenson, Robert H.

PY - 2006/4

Y1 - 2006/4

N2 - Background: There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events. Methods: Using existing data from 2 published clinical trials, we used a resampling method to statistically introduce 5%, 10%, and 20% imprecision to results for B-type natriuretic peptide (BNP) and cardiac troponin I (cTni) and examined its impact on ROC curve analysis. Results: Superimposition of artificial imprecision produced no significant difference in the area under the ROC curve observed for BNP for diagnosis of heart failure or for cTnI for 30-day risk stratification of patients with ACS. Conclusion: Assay imprecision does not appear to be a critical determinant in the interpretation of cardiac marker results for patients with heart disease.

AB - Background: There has been considerable debate regarding the impact of assay imprecision on the performance of cardiac biomarkers for diagnosis of acute coronary syndromes (ACS) and risk stratification for future adverse cardiac events. Methods: Using existing data from 2 published clinical trials, we used a resampling method to statistically introduce 5%, 10%, and 20% imprecision to results for B-type natriuretic peptide (BNP) and cardiac troponin I (cTni) and examined its impact on ROC curve analysis. Results: Superimposition of artificial imprecision produced no significant difference in the area under the ROC curve observed for BNP for diagnosis of heart failure or for cTnI for 30-day risk stratification of patients with ACS. Conclusion: Assay imprecision does not appear to be a critical determinant in the interpretation of cardiac marker results for patients with heart disease.

UR - http://www.scopus.com/inward/record.url?scp=33645451235&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2005.064477

DO - 10.1373/clinchem.2005.064477

M3 - Article

C2 - 16469856

AN - SCOPUS:33645451235

SN - 0009-9147

VL - 52

SP - 752

EP - 753

JO - Clinical Chemistry

JF - Clinical Chemistry

IS - 4

ER -

Influence of imprecision on ROC curve analysis for cardiac markers

Abstract

Access to Document

Other files and links

Fingerprint

Cite this